Nivolumab, an anti-programmed cell death-1 antibody, induces fulminant type 1 diabetes

Tohoku Journal of Experimental Medicine

Volumn 239, Issue 2, 2016, Pages 155-158

  Miyoshi, Yuka ^a   Ogawa, Osamu ^a   Oyama, Yu ^a  

^a KAMEDA MEDICAL CENTER   (Japan)

Author keywords

Autoimmune diseases; Diabetic ketoacidosis; Fulminant type 1 diabetes; Nivolumab; Programmed cell death 1

Indexed keywords

HEMOGLOBIN A1C; INSULIN; NIVOLUMAB; SODIUM CHLORIDE; GLYCOSYLATED HEMOGLOBIN; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CASE REPORT; CONTINUOUS INFUSION; DIABETIC KETOACIDOSIS; DIARRHEA; FEMALE; FULMINANT TYPE 1 DIABETES; FUNCTION TEST; GLUCAGON STIMULATION TEST; HOSPITAL ADMISSION; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; KETONURIA; LABORATORY TEST; LOCAL EXCISION; MELANOMA; METABOLIC ACIDOSIS; NAUSEA; TREATMENT DURATION; VAGINA BLEEDING; VAGINAL MELANOMA; VOMITING; WEIGHT REDUCTION; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 1; IMMUNOLOGY; METABOLISM;

AGED; ANTIBODIES, MONOCLONAL; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84974824547     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.239.155     Document Type: Article

References (14)

1. Adachi, K. & Tamada, K. (2015) Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci., 106, 945-950.
2. Fujisawa, R., Haseda, F., Tsutsumi, C., Hiromine, Y., Noso, S., Kawabata, Y., Mitsui, S., Terasaki, J., Ikegami, H., Imagawa, A. & Hanafusa, T. (2015) Low programmed cell death-1 (PD-1) expression in peripheral CD4(+) T cells in Japanese patients with autoimmune type 1 diabetes. Clin. Exp. Immunol., 180, 452-457.
3. Gaudy, C., Clévy, C., Monestier, S., Dubois, N., Préau, Y., Mallet, S., Richard, M.A., Grob, J.J., Valéro, R. & Béliard, S. (2015) Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care, 38, e182-e183.
4. Hanafusa, T. & Imagawa, A. (2007) Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat. Clin. Pract. Endocrinol. Metab., 3, 36-45.
5. Hughes, J., Vudattu, N., Sznol, M., Gettinger, S., Kluger, H., Lupsa, B. & Herold, K.C. (2015) Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care, 38, e55-e57.
6. Imagawa, A., Hanafusa, T., Awata, T., Ikegami, H., Uchigata, Y., Osawa, H., Kawasaki, E., Kawabata, Y., Kobayashi, T., Shimada, A., Shimizu, I., Takahashi, K., Nagata, M., Makino, H. & Maruyama, T. (2012) Report of the Committee of the Japan Diabetes Society on the research of fulminant and acuteonset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus. J. Diabetes Invest., 3, 536-539.
7. Imagawa, A., Hanafusa, T., Uchigata, Y., Kanatsuka, A., Kawasaki, E., Kobayashi, T., Shimada, A., Shimizu, I., Toyoda, T., Maruyama, T. & Makino, H. (2003) Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care, 26, 2345-2352.
8. Kochupurakkal, N.M., Kruger, A.J., Tripathi, S., Zhu, B., Adams, L.T., Rainbow, D.B., Rossini, A., Greiner, D.L., Sayegh, M.H., Wicker, L.S. & Guleria, I. (2014) Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes. PLoS One, 9, e89561.
9. Martin-Liberal, J., Furness, A.J., Joshi, K., Peggs, K.S., Quezada, S.A. & Larkin, J. (2015) Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol. Immunother., 64, 765-767.
10. Pardoll, D.M. (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer, 12, 252-264.
11. Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J.C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K.J., Hernberg, M.M., Lebbé, C., Charles, J., Mihalcioiu, C., et al. (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med., 372, 320-330.
12. Topalian, S.L., Sznol, M., McDermott, D.F., Kluger, H.M., Carvajal, R.D., Sharfman, W.H., Brahmer, J.R., Lawrence, D.P., Atkins, M.B., Powderly, J.D., Leming, P.D., Lipson, E.J., Puzanov, I., Smith, D.C., Taube, J.M., et al. (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol., 32, 1020-1030.
13. Wang, J., Yoshida, T., Nakaki, F., Hiai, H., Okazaki, T. & Honjo, T. (2005) Establishment of NOD-Pdcd1−/− mice as an efficient animal model of type I diabetes. Proc. Natl. Acad. Sci. USA, 102, 11823-11828.
14. Weber, J.S., D’Angelo, S.P., Minor, D., Hodi, F.S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N.I., Miller, W.H., Lao, C.D., Linette, G.P., Thomas, L., Lorigan, P., Grossmann, K.F., Hassel, J.C., et al. (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol., 16, 375-384.